Metropolis Healthcare Limited (NSE:METROPOLIS)
1,652.50
-25.60 (-1.53%)
Feb 21, 2025, 3:30 PM IST
Metropolis Healthcare Revenue
Metropolis Healthcare had revenue of 3.23B INR in the quarter ending December 31, 2024, with 10.87% growth. This brings the company's revenue in the last twelve months to 13.17B, up 13.60% year-over-year. In the fiscal year ending March 31, 2024, Metropolis Healthcare had annual revenue of 12.08B with 5.18% growth.
Revenue (ttm)
13.17B
Revenue Growth
+13.60%
P/S Ratio
6.43
Revenue / Employee
3.05M
Employees
4,313
Market Cap
84.72B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 12.08B | 594.99M | 5.18% |
Mar 31, 2023 | 11.48B | -801.26M | -6.52% |
Mar 31, 2022 | 12.28B | 2.30B | 23.08% |
Mar 31, 2021 | 9.98B | 1.42B | 16.53% |
Mar 31, 2020 | 8.56B | 952.24M | 12.51% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Metropolis Healthcare News
- 18 days ago - Metropolis Health shares jump 3% as revenue rises 11% YoY in Q3 - Business Upturn
- 19 days ago - Metropolis Healthcare Q3 FY25 results: Revenue Up 9.2% YoY to Rs 29,991.31 lakhs, net profit soars 2.6% YoY - Business Upturn
- 19 days ago - Metropolis Healthcare Ltd (BOM:542650) Q3 2025 Earnings Report Preview: What To Look For - GuruFocus
- 2 months ago - Metropolis Healthcare acquires 100% stake in Core Diagnostics for Rs 246.83 crores - Business Upturn
- 3 months ago - Goldman Sachs maintains ‘Sell’ rating on Metropolis, raises target price to Rs 1,775, expecting 17% downside - Business Upturn
- 6 months ago - Metropolis Healthcare Ltd (BOM:542650) Q1 2025 Earnings Call Transcript Highlights: Strong ... - GuruFocus
- 6 months ago - Q1 2025 Metropolis Healthcare Ltd Earnings Call Transcript - GuruFocus